Skip to content

Quick ratio at other companies

Incyte logo
IncyteINCY
3.5×+1.6×
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
4.2×+0.7×
UroGen Pharma logo
UroGen PharmaURGN
4.3×-1.2×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
1.5×-3.1×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
14×-0.4×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
5.1×-0.7×

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Calculated from Tyra Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s quick ratio?
Tyra Biosciences, Inc. (TYRA) reported quick ratio of 20.5× in Q1 2026.
How has Tyra Biosciences, Inc.'s quick ratio changed year-over-year?
Tyra Biosciences, Inc.'s quick ratio decreased by 10.1% year-over-year, from 22.8× to 20.5×.
What is the long-term trend for Tyra Biosciences, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s quick ratio has grown at a 12.3% compound annual growth rate (CAGR), from 8.2× to 14.7×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.